Facts & figures
Our track record
- #1 uni in Australia for number of active licences, options and assignments.
- #2 uni in Australia for number of active start-ups and spinouts.
Our portfolio of inventions and innovations spans a number of sectors, including diagnostics, therapeutics, biomedical devices and optical technology, just to name a few.
We offer flexible licensing agreements, to streamline the process for our partner organisations.
If you’d like to find out more about the intellectual property we have available for licencing, or our range of licensing/technology transfer options, contact us on +61 2 9351 4000 or via our enquiry form.
We're affiliated with a number of startups and new venture projects that have spun out from our technologies.
Elastagen Pty Ltd is a clinical-stage medical device company that is pioneering Elastatherapy, which uses the human protein elastin to naturally repair and augment the skin.
The company has arisen out of patented research conducted by Professor Tony Weiss’s group and the first clinical trials have demonstrated the biocompatibility and safety of their synthetic human elastin in human subjects.
Elastagen was aquired by leading global biopharmaceutical company, Allergan, in 2018.
Kinoxis Therapeutics Pty Ltd was spun out of the University of Sydney in 2018 and has since raised more than $10M to develop its novel anti-addiction drugs for use in the treatment of substance use disorders and other central nervous system disorders.
The spin off follows years of research led by Professor Iain McGregor, which was the first to show oxytocin administration to laboratory animals causes long-term increases in sociability and a lasting decrease in alcohol and methamphetamine self-administration.
Facts & figures